Pharmaceuticals

IRBM Expands Global Reach in Drug Discovery with New Boston Office

Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...

2024-03-05 20:24 1459

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2024-03-05 13:35 1602

First Patient Treated in Phase 2 GvHD Trial

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...

2024-03-05 10:08 1342

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...

2024-03-05 07:01 1337

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...

2024-03-04 21:19 1730

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...

2024-03-04 16:53 1320

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease

* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 4, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan D...

2024-03-04 16:22 1134

Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2

FORT LEE, N.J., March 2, 2024 /PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr.Rahu...

2024-03-02 10:26 2823

The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Development of TCM Takes Place in Nanyang, China

NANYANG, China, March 2, 2024 /PRNewswire/ -- Co-hosted by the Nanyang Chinese Medicine Development Bureau, the China Association of Chinese Medicine (CACM) and the China Association of Traditional Chinese Medicine (CATCM), the Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Dev...

2024-03-02 05:10 2998

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

* Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. * The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives. * This acquisition is ...

2024-03-01 21:35 3539

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2024-03-01 08:00 2475

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to ...

2024-02-29 17:40 1411

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological ...

2024-02-28 21:32 1142

RRD International is now RRD Biopharma Development

RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model. ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launch...

2024-02-28 21:00 1194

The 20th International Congress on Luobing Theory Held in Shijiazhuang

SHIJIAZHUANG, China, Feb. 28, 2024 /PRNewswire/ -- On February 24, the 20th International Congress on Luobing Theory was held inShijiazhuang, which consisted of 1 main forum and 12 sub-forums. Approximately 20 academicians from both Chinese Academy of Sciences and Chinese Academy of Engineering, ...

2024-02-28 09:37 1084

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide in...

2024-02-28 02:30 1045

Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...

2024-02-27 16:09 1049

Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

* New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing. * The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health n...

2024-02-27 12:40 1129

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...

2024-02-27 07:14 1140

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

MELBOURNE, Australia, Feb. 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based inA...

2024-02-27 05:55 1870
1234567 ... 180

Week's Top Stories